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data, we conclude that drug-resistant viruses, sub-optimal 
drug level, and high baseline viral loads might be probable 
reasons for the prolonged RNA decline only in a sub-set of 
patients. In the absence of emerging DRMs and/or compli-
ance issues, the clinical implications of PV remain unclear; 
however, PV appears to be a risk factor for episodes of 
LLV.
Keywords HIV-1 · Persistent viremia (PV) · Low-level 
viremia (LLV) · Drug resistance · Prolonged decline · 
Antiretroviral therapy
Introduction
After the start of antiretroviral therapy (ART), HIV-RNA 
levels decline in a multiphasic manner. After a rapid drop 
of plasma viral RNA levels in the blood within days, a sec-
ond phase of slower RNA decline below the clinical detec-
tion limit (<50  copies/ml) is observed [1, 2]. Even after 
several years of effective ART, a residual viremia can be 
detected with ultrasensitive methods. The reasons for this 
may be the virus release from reservoirs or remaining viral 
replication [3, 4]. In clinical routine, the goal of antiret-
roviral therapy is to suppress the viral load to undetect-
able levels, which, in clinical practice, is usually achieved 
within 6 months [2, 5]. Since the rate of viral decay after 
ART initiation is related to the half-life of the virus produc-
ing cells [6], a prolonged decline might be associated with 
the presence of long-lived productively infected cells like 
macrophages and latently infected  CD4+ T cells, which can 
be stimulated to produce virus upon interaction with spe-
cific antigens [1]. Furthermore, cells present in sanctuary 
sites, which are difficult to target by the immune response 
and by drugs, were shown to contribute to the HIV-1 RNA 
Abstract After the start of antiretroviral therapy (ART), 
plasma HIV-RNA levels should fall below the limit of 
detection (LOD) within 24  weeks. Hence, the prolonged 
decline of HIV-RNA after ART initiation is defined as 
persistent viremia (PV). In this retrospective study, we 
analyzed factors associated with PV. Next-generation 
sequencing of viral RNA/DNA was performed to study 
viral evolution and the emergence of drug-resistance muta-
tions in HIV-infected patients with PV (n = 20). In addition, 
HIV-DNA species, immunological parameters, and clini-
cal data of the patients were analyzed. We found that the 
possible causes for PV were divers, and both virologic and 
host parameters of this particular cohort were heterogene-
ous. We identified viruses with therapy-associated DRMs 
in six patients (30%); two of these were detected as minor-
ity variants. Five patients had sub-optimal drug levels 
(25%) and the baseline plasma viral loads were relatively 
high. Strikingly, we observed that >40% of the PV patients 
finally reaching HIV levels below the LOD later on showed 
up with episodes of low-level viremia (LLV). However, the 
amount of PBMC derived HIV-DNA species was not corre-
lated with the likelihood of LLV after PV. According to our 
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decline [1, 2, 7–9]. Recently, it has been shown that per-
sistent HIV-1 replication can maintain in tissue reservoirs 
during therapy and that HIV-1 can continue to replicate and 
refill those viral reservoirs despite effective ART [8]. Thus, 
the persistence of virus in cellular reservoirs can negatively 
influence effective suppression [10, 11].
In addition, strict compliance with the ART is a crucial 
precondition to sustainable control of HIV viral load and 
to low risk of developing drug resistance. Here, sub-opti-
mal ART adherence was associated with increased residual 
virus quantity; however, residual viremia can also occur in 
complete ART adherence [3, 12]. Furthermore, malabsorp-
tion, insufficient dosage, drug–drug interactions, impaired 
intracellular metabolism, P450 hyperactivity, and P glyco-
protein overexpression might have a tremendous effect on 
ART efficacy [13].
In a recent study, it has been shown that patients having 
a high pre-ART pVL show a poor probability of achieving 
viral suppression when compared to patients with lower BL 
pVL [4, 14]. In particular, patients with >500,000 copies/
ml showed a low probability to achieve viral suppression 
within 72 weeks [15].
The emergence of drug-resistance mutations (DRMs) 
is one of the major causes leading to therapy failure. Here, 
pre-existing drug-resistant HIV strains can also have dra-
matic impact on ART efficacy. In particular, transmit-
ted variants carrying DRMs are found in approx. 10% 
(12.6% in USA and 8.8% in Europe) of treatment-naïve 
(TN) patients [16, 17]. In addition, the high-error rate of 
the virus encoded reverse transcriptase (RT) might also 
facilitate the early selection of drug-resistant HIV already 
present at ART baseline as minority variant in the pool of 
quasi species [18–20]. Particularly, patients with prolonged 
viral decline were shown to have a high risk of selecting 
drug-resistant viruses [21].
So far, the underlying mechanism of PV has, however, 
remained elusive. Thus, in this study, we analyzed patients 
with persistent HIV viremia and studied the clinical pat-
terns of PV, the viral evolution of DRMs using next-gener-
ation sequencing (NGS), and the long-term outcome after 




As a part of a retrospective analysis of HIV-1 positive 
patients treated with antiretroviral therapy (ART) in the 
HIV outpatient center at the University Hospital Essen 
(Germany) from 2013 to 2016, we studied 20 individu-
als who had pVL > 50 copies/ml for longer than 24 weeks 
after the start or restart of antiretroviral treatment (Table 1; 
Table 1  Participant 
characteristics
Patient parameters were analyzed before ART initiation (base line = BL) and during persistent viremia at 
the time point of genotyping (GT). Flow cytometric determined CD4+ T-cell levels were obtained from 
routine diagnostics
ATV Atazanavir, DRV Darunavir, LPV Lopinavir, EFV Efavirenz, RAL Raltegravir, EVG Elvitegravir, DTG 
Dolutegravir, /r boosted with Ritonavir, IQR interquartile range, BL Baseline, GT genotyping, LOD limit of 
detection (<50 HIV-1 RNA cp/ml)
n = 20 Baseline (Pre-ART), median (IQR) Genotyping (during 
ART) median (IQR)
HIV-1 RNA (cp/ml) 302,000 (39,473; 744,150) 136 (76; 300)
Immunological parameters
 CD4+ T cells/µl 105.5 (55.5; 286.8) 294 (234; 364)
 HLA-DR+ T cells/µl 387 (177; 591) 301 (128; 473)
 Ratio CD4/CD8 0.21 (0.095; 0.42) 0.56 (0.3; 0.56)
Antiretroviral treatment (ART)
 Duration
  BL → GT (days) 237 (172; 318)
  BL → LOD (days) 459 (342; 649)
Regimens (%)
 DRV/r + 2 NRTI 12
 ATV/r + 2 NRTI 1
 LPV/r + 2 NRTI 2
 EFV + 2 NRTI 2
 RAL/EVG + 2 NRTI 2
 DRV/r + DTG 1
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Fig. 3). This study has been approved by the Ethics Com-
mittee of the medical faculty of the University Duisburg-
Essen (14-6155-BO) and has been registered with the Clin-
icalTrials.gov database under No. NCT02411071.
HIV quantification and genotyping analysis
Plasma HIV-RNAs were quantified using the Abbott 
RealTime HIV-1  m2000 test system as described by the 
manufacturer. Viral RNA and the corresponding proviral 
DNA of the 20 EDTA samples were isolated, amplified, 
sequenced [protease (PR) and reverse transcriptase (RT)], 
and analyzed for the presence of drug-resistance mutations 
(DRMs). Here, HIV-RNA and DNA were isolated using 
QIAamp Viral RNA Kit (Qiagen) and QIAamp DNA Blood 
Mini Kit (Qiagen), respectively, according to the manufac-
turer’s instructions. RNA was reverse transcribed using 
one-step RT-PCR kit (Qiagen), and PR and RT sequences 
were amplified using the Hot-StarTaq polymerase kit (Qia-
gen) according to a nested PCR protocol published previ-
ously [22]. Accordingly, DNA was subjected to the same 
nested PCR procedure. The genetic diversity of each sam-
ple was analyzed by next-generation sequencing (NGS) 
using the Illumina MiSeq platform during ART, which 
was compared to HIV drug-resistance tests previously per-
formed in routine diagnostics (Sanger Sequencing). DRMs 
as listed by the International AIDS Society (IAS) were 
scored as major variants when detected in more than 10% 
of the reads and as minority variants when detected in less 
than 10%. As far as possible, the resistance testing of sam-
ples with low viral load was performed from RNA (n = 16); 
otherwise, proviral DNA was sequenced (n = 20).
Measurements of HIV total, integrated proviral, 
and episomal 2-LTR circle DNA
Total and integrated proviral as well as two long terminal 
repeat (2-LTR) circle HIV-DNA were quantified using a 
pre-PCR followed by a real time PCR as described previ-
ously [23]. Briefly, peripheral blood mononuclear cells 
(PBMCs) were extracted by Ficoll centrifugation using 
LEUCOSEP tubes with porous barrier (grainer bio-one) 
and the DNA was isolated using QIAamp DNA Blood Mini 
Kit (Qiagen) according to the manufacturer’s instructions. 
To maintain exponential amplification, 12 cycles of HIV-
DNA and the CD3 gene preamplification were carried out 
using thermal cycler T professional Trio (Biometra). The 
pre-PCR products were diluted and used as templates for 
the second round of amplification, which was performed on 
a Rotor-Gene-Q instrument (Qiagen). Standard curves were 
created with plasmid DNA templates harboring the ampli-
con sequences. A plasmid-containing nucleotide sequences 
from the human CD3gamma and HIV-1 pNL4-3 [24] 
derived 2-LTR circles (pEX-K4-2-LTR-CD3) was synthe-
sized and purchased by Eurofins Scientific. For total HIV 
determination, the pre-PCR amplicon was cloned using 
PCR cloning kit (NEB) resulting in the plasmid pMiniT 
NL4-3 LTR-In1. For the generation of the PCR standard for 
quantitative Alu PCRs, genomic DNA from LTR-contain-
ing TZM-bl cells was isolated using QIAamp DNA Blood 
Mini Kit (Qiagen) according to the manufacturer’s instruc-
tions and copy-corrected by calculation of the LTR/CD3 
ratio. All PCR standards were prepared by serial tenfold 
dilutions.
Liquid chromatography–mass spectrometry 
for drug-level analysis
Following a protein precipitation, drug levels were deter-
mined by an in house high-performance liquid chromatog-
raphy–mass spectrometry (HPLC/MS/MS). Quantifica-
tion was performed on the basis of a dilution series used 
on each run. Each controls for low and high are based on 
weighing of pure substance. For evaluation of the drug effi-
cacy, the trough levels (Cmin) of each drug were correlated 
to the corresponding therapy application. The Cmin and 
Cmax values are obtained from the average measured values 
after intake in healthy volunteers as described in the corre-
sponding patient information leaflet provided by the manu-
facturer. For darunavir, there are two Cmin and Cmax values 
depending on the mode of ingestion.
Statistical analysis
The statistical significance of the different decline periods 
between ART initiation and first pVL <50  copies/ml of 
patients with and without treatment switch during PV was 
estimated by performing a two-tailed Mann–Whitney test. 
Significance of correlation was calculated using two-tailed 




In our study, 15 patients received a first-line therapy (FL), 
while five of them were treatment experienced and restarted 
ART after treatment interruption. Before ART initiation, 
the median pVL was 302,000 copies/ml and dropped to 136 
copies/ml during 237 days (IQR 172; 318) with ART at the 
time of genotyping. The overall pVL decline after the ART 
initiation (if has been successful) required 459 days (IQR 
342; 649) to reach pVL <50  copies/ml (n = 17). Three 
patients did not reach pVL below the LOD and were lost to 
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follow up. 16 of the 20 patients were treated with a PI-con-
taining regimen combined with a NRTI-backbone, whereas 
only few of them received treatment regimens based on 
integrase inhibitors (INSTI) or NNRTI (Tables  1, 2). As 
determined by Sanger sequencing of proviral DNA, only 
in a single patient (PV-04), HIV carrying the RT associ-
ated M184V drug-resistant mutation (DRM) was detected 
in routine diagnostics prior to the therapy switch. Over-
all, patients in this analysis cohort had relatively low CD4 
counts and high plasma HIV-1 RNA levels. As shown in 
Table 1, median baseline HIV-1 RNA level (pre-ART) was 
302,000 (39,473; 744,150) copies/ml. Median baseline 
(BL) CD4+ T cells level was 105.5  cells/µl (55.5; 286.8) 
with a CD4/CD8 ratio of 0.21 (0.095; 0.42). CD4+ levels 
as measured at times genotyping (GT) was 294  cells/µl 
(234; 364) with a CD4/CD8 ratio of 0.56 (0.3; 0.56). The 
pre-ART HLA-DR+ T-cell level was 387  cells/µl (177; 
591) and dropped to 301  cells/µl (128; 473) during ART. 
Samples were obtained between the 26th and 52nd week 
after ART start or restart. Only in three therapy-experi-
enced (TE) patients (PV-18, PV-19, and PV-20), samples 
were collected at a later time after ART restart, which were 
between the 65th and 117th week.
DRMs detected in PV patients
To investigate whether a prolonged HIV-RNA decline 
might be correlated with the emergence of DRMs, we used 
next-generation sequencing (NGS) and sequenced plasma 
RNA as well as proviral DNA derived PCR amplicons. 
We identified viruses with therapy-associated DRMs in six 
patients (30%). As shown in Table 2, M184V was detected 
in the DNA derived from PV-04, which was already pre-
sent before ART switching (see above). In patient PV-07, 
we identified G190A in both RNA and DNA derived sam-
ples indicating resistance to EFV, which was used as part 
of the first-line therapy. In patient PV-10, we detected the 
major NRTI mutation M184V in RNA indicating a resist-
ance to FTC as part of the current ART regimen. Analyz-
ing proviral DNA isolated from patient PV-19, we also 
detected a further mutation M184V. We were able to deter-
mine PI-associated DRMs in patient PV-16 in the minori-
ties of the reads obtained from RNA (V82A; 2%). Further-
more, we identified M46I as a minority variant in 5% of 
proviral DNA in patient PV-03. In four patients (20%), we 
found DRMs, which were not related to the current therapy 
regiment but might be related to transmitted DRMs (FL, 
PV-10) or associated with previously used therapy regi-
mens (TE, PV-16; PV-18; and PV-20). Since DRMs were 
only found in 25% of the analyzed RNA and DNA samples 
obtained from PV patients DRMs seem not to be consid-
ered as the only reason of PV in our cohort.
Drug-level measurement in PV patients
Since reduced drug absorption might be another cause 
for PV, we analyzed the drug-level concentrations in each 
patients plasma at the time of genotyping. In most cases, 
drug levels were found to be in the therapeutic range 
(Tables  2, 3). However, in 25% of the patients (n = 5; 
PV-02, PV-13, PV-16, PV-17, and PV-18), we found that 
the concentration of at least one drug of the current ART 
regime was below the therapeutic drug level Cmin. In one of 
these cases, also a new DRM was detected during PV (PV-
16: V82A). Hence, sub-optimal drug levels can also be a 
reason for PV in a sub-set of patients.
Impact on BL pVL and therapy switching on RNA 
decline duration
The duration of PV has been correlated with pVL before 
ART initiation where patients with high BL pVL showed 
a longer decline period when compared to those with low 
BL pVL [4, 14]. Furthermore, patients having a high BL 
pVL prior to ART begin (>500,000  copies/mL) were 
shown to have a poor probability to achieve full viral sup-
pression [15]. Since most of the patients in our cohort had 
pVL >100,000 copies/ml (~80%, Table 2), which is defined 
as very high, our data suggest that high virus load levels 
might be considered as another reason for the prolonged 
virus decay. Because the patients analyzed in this study 
were already selected on the basis of the prolonged decline 
period, we did not observe significant different RNA 
decline durations within sub-groups (data not shown).
55 percent of the PV patients (n = 11) underwent a ther-
apy switch (Table 2; PV-01 – PV-09, PV-16, and PV-18). 
Ten of them reached pVL below LOD after averagely 46.7 
(±31.2) weeks after ART initiation and PV-18 was lost to 
follow up. In three of these patients, DRMs were detected 
(PV-03, PV-04, PV-07). Out of the group of patients with-
out therapy switch (n = 9), seven patients reached sup-
pressed pVL within 17.2 (+/- 9.2) weeks (PV-10–PV-14 
and PV-19–PV-20). Comparing the average time of decline 
for the groups with and without therapy switch, respec-
tively, there was no significant difference (Fig.  1). These 
results indicate that a switch of ART without a mutation-
related indication has no beneficial impact on the outcome 
of PV.
HIV-1 persistent viremia is often followed by low-level 
viremia
We investigated whether PV might be associated with the 
occurrence of blips or of episodes of low-level viremia 
(LLV) during the follow-up time after the patients have 
reached pVL below the LOD. Here, a blip was defined as 
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single virus detections that indicates transient viremia only, 
while, in contrast, LLV was defined as at least two consecu-
tive pVL (>50 RNA copies/ml and <1000 RNA copies/ml). 
For this analysis, we only included patients who received 
a first-line therapy and who reached pVL <50 RNA cop-
ies/ml (n = 14; PV 01–PV14). As shown in Table  2 and 
Fig. 2a, we observed that 42.9% (n = 6/14) of these patients 
showed sustained suppression of HIV-RNA. However, 
most interestingly, we found that the percentage of patients 
who showed up with episodes of LLV after reaching <50 
pVL was particularly high. Here, 42.9% (n = 6) of patients 
with PV showed up with low-level viremia (LLV) during 
the follow-up time, which, in general, was more than three-
fold higher tendency compared to approx. 12% in non-PV 
patients (see also in the “Discussion” section) [25, 26]. 
Subsequent blips were observed only in 21.4% (n = 3) of 
the patients.
Based on this finding, we sub-divided the group of 
patients finally reaching LOD (<50) regardless whether 
they received the first-line or multi-line therapy (n = 17) 
into two smaller groups. We compared the outcome of the 
group of patients having low drug levels (LD) or drug-
resistant viruses (n = 8) with the group of patients without 
these features (n = 9) but did not found different frequen-
cies of LLV experience after PV. Interestingly, we did not 
observe blips in the group without LD and DRMs, while 
the blip frequency in the other group was comparable to 
studies published previously [25, 26].
Thus, our data indicate that the risk of experiencing epi-
sodes of LLV tended to be especially high in patients who 
have shown up with PV.
The probability to show up with low-level 
viremia after reaching the LOD is not correlated 
with HIV-DNA levels
We next raised the question whether the size of the viral 
reservoir measured as levels of HIV-DNA in PBMCs might 
be correlated with the occurrence of PV or LLV. Thus, we 
quantified non-integrated viral DNA, which can be meas-
ured by total HIV-1 DNA, integrated proviral DNA as well 
as 2-LTR circles derived from PBMCs that were collected 
during PV.
As shown in Fig.  2b, we compared the groups of PV 
patients experiencing LLV with the group of long-term 
suppressed patients with respect to the amounts of viral 
DNA. However, we did not find significant differences 
between the groups (Fig. 2b). Comparing the sub-groups of 
PV patients with and without drug-resistant viruses and low 
drug levels, respectively, we also were not able to observe a 
significant difference (data not shown). Thus, based on our 
data, we could not correlate the amounts of proviral DNA 
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putative size of the viral reservoir at least at times of geno-
typing seems not to be a suitable marker to predict episodes 
of LLV that emerge after PV.
Discussion
In this retrospective study, we analyzed 20 PV patients 
after the start or restart of antiretroviral treatment regimens. 
We found that DRMs and intermitted low drug levels could 
be considered as probable reasons for PV only in a sub-set 
of PV patients. Since the baseline pVL in this group was 
relatively high, we also suggest that high virus load lev-
els might be another possible reason for a prolonged virus 
decay. Furthermore, the switch of ART does not per se 
have a beneficial impact on the outcome of PV in absence 
of DRMs. Most strikingly, we found that the risk of expe-
riencing episodes of LLV tended to be especially high in 
patients who have shown up with PV when compared to 
previously published studies [25, 26]. Nevertheless, we 
found that the amounts of HIV-1 DNA species at least at 
times of genotyping were not an appropriate marker to pre-
dict episodes of LLV that emerge after PV.
Up to now, it has remained unclear whether the pro-
longed decline of HIV-1 pVL is related to pre-existing 
drug-resistant variants, the emergence of new DRMs or 
low drug levels. In a recent study, it has been shown that 
patients irrespective of therapy changes having a high pre-
ART pVL (>500,000  copies/mL) show a low probability 
of achieving viral suppression within 72 weeks [15]. When 
analyzing our entire group of PV patients or sub-groups 
with high and low BL pVL, however, we did not find a 
significant correlation between pVL BL and the duration 
of PV, even though patients with PV tend to have high 
baseline viral loads (>500.000 copies/mL). Most of the 
patients in this cohort had pVL >100,000 copies/ml which 
is defined as very high. As shown in Table 1, median base-
line HIV-1 RNA level (pre-ART) was 302,000 [39,473; 
Table 3  LC-MS drug-level quantification of patient with persistent viremia at time point of genotyping
Drug levels at time point of genotyping were quantified using HPLC/MS/MS as described in the method section. In addition, two internal con-
trols (Control_1; Control_2) were used as references. Bold values indicate too low concentration of the indicated drug (<Cmin). DRV 1*800 
indicates a dosing scheme of 800 mg darunavir once-daily, DRV2*600 refers to the dosing of 600 mg twice-daily. The Cmin and Cmax values 
are obtained from the patient information leaflets provided by the manufacturer. Regardless of the mode of ingestion, values for darunavir were 
available for twice-daily (DRV 2*600) only. All values are given in ng/ml
ID ART NNRTI NRTI PI INI
EFV TDF FTC ATV DRV 2*600 DRV 1*800 LPV cobi rtv RAL EVG DTG
PV-01 ABC, 3TC, DRV/r – – – – – 6370 – – 1020 – – –
PV-02 FTC, TDF, DRV/r – 224 532 – 2100 – – – 1060 – – –
PV-03 TDF, FTC, ATV/r – 65.4 798 2900 – – – – 1430 – – –
PV-04 TDF, FTC, DRV/r – 148 259 – – 2580 – – 185 – – –
PV-05 TDF, FTC, RAL – 94.4 1460 – – – – – – 2600 – –
PV-06 TDF, FTC, EVG – 279 1140 – – – – 1810 – – 1960 –
PV-07 TDF, FTV, EFV 1070 65.4 201 – – – – – – – – –
PV-08 TDF, FTC, DRV/r – 63.8 203 – – 4470 – – 150 – – –
PV-09 TDF, FTC, DRV/r – 63.2 203 – – 1980 – – 286 – – –
PV-10 FTC, TDF, DRV/r – 271 890 – – 6440 – – 159 – – –
PV-11 TDF, FTC, EFV 1260 75.1 202 – – – – – – – – –
PV-12 TDF, FTC, DRV/r – 127 1910 – – 7360 – – 513 – – –
PV-13 TDF, FTC, DRV/r – – – – – 687 – – – – – –
PV-14 TDF, FTC, DRV/r – 191 1220 – – 3750 – – 308 – – –
PV-16 FTC, TDF, LPV/r – 52.2 66.7 – – – 257 – 25.2 – – –
PV-17 TDF, FTC, DRV/r – – 69.9 – – 986 – – 14.7 – – –
PV-18 DRV/r, DTG – – – – – 1270 – – 67,6 – – 811
PV-19 TDF, FTC, DRV/r – 78.5 215 – – 1950 – – 151 – – –
PV-20 ABC, 3TC, DRV/r – – – – – 5320 – – 578 – – –
Control_1 3820 2500 1540 1500 1550 1550 3970 1510 2120 1670 1190 1950
Control_2 833 552 355 345 375 375 945 381 438 371 273 442
Cmin 750 20 20 157 2430 841 1500 38 40 70 190 1110
Cmax 5250 2500 2500 6340 6500 6060 14,000 1500 1230 2200 2090 4150
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744,150] copies/ml. Furthermore, the median baseline (BL) 
CD4+ T-cell level was low 105.5 (55.5; 286.8). Thus, the 
combination of high pVL and low CD4+ T-cell level might 
be another causative reason for prolonged RNA decline in 
this cohort.
In former studies, a significant higher risk for the devel-
opment of drug resistance was detected in patients whose 
viral load decreased with a relatively slow rate [21]. In 
our study, we identified six patients (30%) carrying drug-
resistant viruses; three of these were found in RNA sam-
ples. Although using NGS, we were able to identify minor-
ity variants carrying therapy-associated DRMs in two 
patients. Summarizing, persistent viral replication was at 
least in part (30% of the patients) associated with the detec-
tion of drug-resistant HIV variants. Noteworthy, NGS was 
shown to be a highly sensitive sequencing method allowing 
the identification of sub-populations at earlier time points. 
In addition, when compared to Sanger sequencing, sig-
nificantly, more data are generated improving the quality. 
Hence, NGS has proven to be very helpful in clinical prac-
tice allowing an earlier adjustment of the individual ART, 
which might also be helpful to monitor patients with PV. 
Low drug levels related to poor adherence, malabsorption, 
insufficient dosage, drug–drug interactions, impaired intra-
cellular metabolism, P450 hyperactivity, and P glycopro-
tein overexpression might have a tremendous effect on ART 
efficacy [13]. In our patient cohort, sub-optimal drug level 
was the probable reason for the prolonged RNA decline 
in a sub-set of patients (20%). Comparing the course of 
viral load decline of patients with sub-optimal drug-level 
(PV-02, PV-15, and PV-18), repeatedly temporarily insuf-
ficient viral suppression becomes obvious. Here, ups and 
downs of HIV-RNA levels without changing ART are 
hints for compliance issues (Fig. 3). However, the distinc-
tion between adherence disorders and resorption was not 
possible and specific metabolism problems of each patient 























Fig. 1  Duration of PV in patients with and without therapy switch: 
Median (IQR) of decline periods between genotyping and first 
pVL < LOD of patients with (+TS) and without treatment switch (−
TS) after genotyping. Patients who were switched due to DRMs were 






















Fig. 2  Persistent Viremia is often followed by LLV. a Follow-up 
events (no events, transient HIV-1 RNA blips, showing up with epi-
sodes of low-level viremia) of patients who received a first-line ther-
apy and who reached pVL <50 RNA copies/ml were depicted (left). 
Sub-analysis of patients reaching pVL <50 who had low drug levels 
as well drug-resistant viruses (middle) and those who had not (right). 
b Total HIV-1 DNA, integrated proviral DNA, and non-integrated 
viral DNA (2-LTR circles) were determined using DNA isolated 
from PBMCs collected at time point of genotyping. The lines indicate 
mean values
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with sufficient drug-levels in therapeutic drug monitoring 
(TDM), adherence disorders may have caused poor drug 
availability. For the remaining 50% of PV patients without 
drug-resistant viruses and low drug levels, it is tempting to 
speculate that the size of the viral reservoir was extraordi-
nary high, which was the reason why the viral load decline 
took longer than usually observed in clinical practice [5], 
even though we were not able to observe any correlation 
with HIV-DNA levels obtained from PBMCs and PV. 
However, the initial baseline viral load, which might give a 
hint for the size of viral reservoir [27], was shown to influ-
ence the decline [4, 14]. In particular, Maldarelli et al. stud-
ied 145 patients whose pVL dropped below LOD within 
24 weeks after ART initiation and found a significant cor-
relation by comparing pVL at week 60 to those determined 
before ART initiation [14]. Furthermore, they found that 
both the extent of pVL reduction and the level of PV were 
not associated with pre-therapy CD4+ T-cell count and 
change in CD4+ T-cell count on therapy. In this respect, 
it has also been shown that HIV-1 RNA may decline more 
slowly, because long-lived cells are not reached by immune 
response like  CD8+ cells and by antiretroviral drugs [8, 
28]. Here, the loss of long-lived HIV-infected cells was 
shown to be a major contributor to pVL decline, whereas 
the activation of latently infected lymphocytes was only 
a minor contributor [2]. Ongoing HIV-1 replication was 
shown to be associated with low drug levels measured in 
lymphatic tissues, and hence, HIV replication can continue 
and make up the viral reservoir despite potent ART [8, 28]. 
In this respect, it has been shown that ART itself can influ-
ence the existing reservoir. In particular, boosted dual pro-
tease inhibitor regimens have a poor ability to penetrate the 
blood–brain barrier, which can result in residual HIV rep-
lication in the CNS [9]. Thus, there is an urgent need for 
novel parameters describing ongoing replication in certain 
compartments and tissues, i.e., sanctuary sites of replica-
tion, as well as therapeutical possibilities to intervent or 
improve the possibility to penetrate the replication sites.
The importance of the viral reservoir, additional host 
factors, or compliance issues as the underlying reason for 
PV is further emphasized by the fact that patients with 
PV in this study were especially prone to show up with 
low-level viremia episodes during the follow-up time. We 
found that the rebound probability and risk to show up with 
LLV after a period of PV were more than threefold higher 
(~43%) when compared to the above-mentioned studies 
by Moore et al. and Sklar et al. (~12%) [25, 26]. Here, in 
the cohort study of Sklar et  al., 448 patients on ART on 
both PI-based and non-PI-based regimens with pVL copies 
<50 copies/ml were followed over 69 weeks. Once reached 
pVL <50  copies/ml, 4.2% had lasting low-level-viremia 
<400  copies/ml and 7.4% had lasting high-level viremia 
>400 copies/ml, which was 11.6% in total [26]. In addition, 
27.2% had transient viremia only. In the study of Moore 
et al., 553 patients on ART (73% on PI regimen) with pVL 
copies <50 copies/ml were followed over 56 weeks. Here, 
patients were analyzed being under the limit of detection 
up to 120 weeks. In average, analyzing these patients 35% 
had blips, while 12.8% had at least two RNA measure-
ments >50  copies/ml. In our study, blips were observed 
more frequently in the group of patients having low drug 
levels and/or drug-resistant viruses when compared with 
those patients who did not. Blips are frequently seen even 
in patients who are effectively suppressed for years. This 
might be explained due to immune activation related to, 
for instance, respiratory infections or vaccination but are 
not correlated with treatment failure [29, 30]. However, 
blips might at least in a sub-set of patients also be associ-
ated with compliance issues. Importantly, the detection of 
consecutive pVL is suspicious for ongoing viral replication 
[31]. It has been also shown that LLV may be predictive for 
viral rebound and that resistance mutations emerging dur-
ing episodes of low-level viremia might lead to virological 
failure [32–35].
Since the overall number of patients in our study was 
low and multiple factors seemed to independently influ-
ence the occurrence of PV, this study has certain limita-
tions. In addition, the patients studied were treated with 
different ART regimens, so the influence of drugs on PV 
could not be adequately evaluated. In a comparative analy-
sis of treatment-naïve patients receiving NRTI and INSTI 
versus NNRTI and boosted PI, for instance, the benefit of 
INSTI, in particular raltegravir, on RNA plasma decline 
comes obvious [36]. Since the patients, in our study, have 
been treated in the time period from 2012 till 2015, a high 
frequency of PI-based ART can be observed. Only two 
patients received NRTIs + INSTI as first-line therapy and 
six patients switched their ART to an INSTI-containing 
regimen. A comparison of these unequal groups was, there-
fore, not possible; however, it will be interesting to inves-
tigate newly acquired data on this comparison in future 
studies. Since it was not possible to uniformly collect drug 
level data in this study population, we compared Cmin val-
ues of each drug and therapy application form to determine 
whether drug levels were available in sufficient quantities. 
The drug levels were measured only once at the time of 
genotyping, so that only a strong generalized representation 
is possible. Although our sample size was small, this work 
clearly showed the heterogeneity of the underlying factors 
of PV and the urgent need of identifying markers for clas-
sifying PV according to its clinical outcome. The major 
finding of this study, however, was the observation that PV 
appears to be a risk factor for undergo episodes of LLV.
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